Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
EPA DSSTox provides the canonical identifier, structure, and synonym profile for this chemical.
Concern score
The concern value is driven by the published classifications and regulatory status below — not by a single signal.
Concern score 45/100 (moderate) · high confidence.
Prevalence of SODIUM PHOSPHATE, DIBASIC in our catalog (fda_ndc).
Products
18
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
FDA
Route: INTRADERMAL; Dosage form: INJECTION; Potency: 0.2 %w/v
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Potency: 40 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 40 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION; Potency: 200 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 40 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION; Potency: 0.43 %w/w
US
FDA
Route: ORAL; Dosage form: CONCENTRATE; Potency: 17 mg/5ml
US
FDA
Route: ORAL; Dosage form: FILM, SOLUBLE; Maximum daily exposure: 9 mg
US
FDA
Route: ORAL; Dosage form: SOLUTION; Potency: 40 mg/1ml
US
FDA
Route: ORAL; Dosage form: SYRUP; Maximum daily exposure: 70 mg
US
FDA
Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Maximum daily exposure: 143 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION; Maximum daily exposure: 14 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 2.98 mg
US
FDA
FDA NDC lists this ingredient in 17 active drug products and 18 total products.
US
FDA
openFDA substance registry classifies this ingredient as mixture.